Note 11 - Segment Reporting (Tables)

12 Months Ended

Jun. 30, 2017

Notes Tables

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Year Ended June 30, 2017
	Clinical Development			Device			Total
Net revenues	$	492,000		$	14,033,000		$	14,525,000
Cost of revenues		466,000			8,220,000			8,686,000
Gross profit		26,000			5,813,000			5,839,000
Operating expenses		8,966,000			6,113,000			15,079,000
Operating profit (loss)	$	(8,940,000	)	$	(300,000	)	$	(9,240,000	)
Depreciation and amortization	$	501,000		$	329,000		$	830,000
Stock-based compensation expense	$	970,000		$	491,000		$	1,461,000

	Year Ended June 30, 2016
	Clinical Development			Device			Total
Net revenues	$	646,000		$	11,283,000		$	11,929,000
Cost of revenues		574,000			8,611,000			9,185,000
Gross profit		72,000			2,672,000			2,744,000
Operating expenses		8,312,000			5,297,000			13,609,000
Operating profit (loss)	$	(8,240,000	)	$	(2,625,000	)	$	(10,865,000	)
Depreciation and amortization	$	644,000		$	524,000		$	1,168,000
Stock-based compensation expense	$	548,000		$	194,000		$	742,000